ACS患者PCI术后P2Y12抑制剂依从性轨迹及其预后意义
共识别出五种依从性轨迹,其中快速下降和延迟启动与更高的MACE风险相关,而早期持续不依从仅在药物洗脱支架亚组中与更高的MACE风险相关。
要点
- PCI后一年内P2Y12抑制剂依从性可分为五种不同轨迹。
- 快速下降和延迟启动与更高的MACE风险独立相关。
- 早期持续不依从仅在药物洗脱支架患者中与更高MACE风险相关。
核心结论
- ACS患者PCI术后P2Y12抑制剂依从性存在五种不同轨迹,快速下降和延迟启动与更高MACE风险相关,早期持续不依从仅在药物洗脱支架亚组中与更高MACE风险相关。
主要发现
- 识别出五种依从性轨迹:早期持续不依从(11.0%)、快速下降(7.7%)、延迟启动(6.0%)、逐渐下降(20.5%)和持续依从(54.8%)。
- 与持续依从相比,快速下降(HR 1.23,95%CI 1.01-1.49)和延迟启动(HR 1.41,95%CI 1.12-1.78)与更高的MACE风险相关。
- 早期持续不依从仅在药物洗脱支架亚组中与更高的MACE风险相关(HR 2.44,95%CI 1.60-3.71)。
临床怎么用
- PCI术后应关注P2Y12抑制剂依从性轨迹,尤其警惕快速下降和延迟启动模式,对药物洗脱支架患者需特别关注早期持续不依从。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Post-acute coronary syndrome (ACS) P2Y12 inhibitor non-adherence is common and associated with greater risk of major adverse cardiovascular events (MACEs). Non-adherence can follow different trajectories from an inability to initiate, implement, or continue therapy for the intended duration. We aimed to evaluate P2Y12 inhibitor adherence trajectories among ACS patients treated with percutaneous coronary intervention (PCI), their frequency, and association with MACE. METHODS AND RESULTS: We conducted a cohort study of adults discharged alive after PCI for ACS (2012-16) using the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry linked with administrative data. The primary outcome was P2Y12 inhibitor adherence trajectory in the year after PCI assessed using group-based trajectory modelling. We used logistic regression and Cox proportional-hazards regression to assess associations of trajectories with risk factors and MACE, respectively. We included 12 844 patients (mean age 62.4 years, 23.6% female). Five trajectories were identified: early consistent non-adherence (11.0%), rapid decline (7.7%), delayed initiation (6.0%), gradual decline (20.5%), and persistent adherence (54.8%). Compared with persistent adherence, rapid decline [hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.01-1.49] and delayed initiation (HR 1.41, 95% CI 1.12-1.78) were associated with higher MACE in the overall cohort, whereas early consistent non-adherence was associated with higher MACE only in the subgroup receiving a drug-eluting stent (HR 2.44, 95% CI 1.60-3.71). CONCLUSION: After PCI for ACS, patients followed one of five distinct P2Y12 inhibitor adherence trajectories. Rapid decline and delayed initiation were associated with a higher risk of MACE, whereas early consistent non-adherence was only associated with higher MACE risk in patients with a drug-eluting stent.
引用
- Turgeon, Koshman, Dong, et al. P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications. Eur Heart J. 2022. PMID: 35296876. doi:10.1093/eurheartj/ehac116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。